TOPICAL CORTICOSTEROIDS AND UNWANTED LOCAL-EFFECTS - IMPROVING THE BENEFIT RISK RATIO

被引:30
作者
MORI, M [1 ]
PIMPINELLI, N [1 ]
GIANNOTTI, B [1 ]
机构
[1] UNIV FLORENCE,DERMATOL CLIN 2,VIA PERGOLA 58,I-50121 FLORENCE,ITALY
关键词
D O I
10.2165/00002018-199410050-00005
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The main goal of pharmacological research in the field of topical corticosteroids (TCs) is to dissociate efficacy and adverse effects as much as possible. The optimal use of TCs, i.e. the careful evaluation of the benefit/risk ratio, depends on: (i) the chemical structure of the TC; (ii) the type of vehicle, (iii) the mode of application; and (iv) the features of the skin to be treated. The recent availability of TCs characterised by a good dissociation between efficacy and adverse effects makes the classic and widely used classification system of TCs based upon potency out of date. Indeed, TCs with increasing potency have been characterised up to now, as a rule, by an increasing risk of adverse effects. Therefore, a classification system taking into major account the benefit/risk ratio seems particularly needed for clinical use in dermatology.
引用
收藏
页码:406 / 412
页数:7
相关论文
共 56 条
  • [1] Barry B.W., Bioavailability of topical steroids, Dermatologica, 152, 1, pp. 47-65, (1976)
  • [2] Bateman D.N., Clinical pharmacology of topical steroids, Pharmacology of the skin II, pp. 239-249, (1989)
  • [3] Bodor N., Farag H.H., Improved delivery through biological membranes, Journal of Medicinal Chemistry, 26, pp. 313-318, (1983)
  • [4] Budgaard H., Hansen J., Studies on the stability of cortico steroids. Kinetics of the rearrangement of betamethasone-17-valerate to the 21-valerato ester in aqueous solution, International Journal of Pharmaceutics, 7, pp. 197-203, (1981)
  • [5] Chernosky M.E., Schmidt J.D., Atrophy, telangiectasia and purpura after topical fluorinated corticosteroid therapy, Cutis, 13, pp. 383-386, (1974)
  • [6] Cheung Y.W., Liwan P.A., Irwin W.J., Resistance to enzymatic hydrolysis as a pameter in drug potency, International Journal of Pharmaceutics, 27, pp. 325-333, (1985)
  • [7] Cullen, Effective topical dermatologic therapy, Dermatologic Clinics, 7, pp. 37-42, (1989)
  • [8] Deakin M.J., Current dangers and problems in the topical use of steroids, Medical Journal of Australia, 1, pp. 120-121, (1976)
  • [9] du Vivier A., Tachyphylaxis to topically applied steroids, Archives of Dermatology, 112, pp. 1245-1248, (1976)
  • [10] Dykes P.J., Hill S., Marks R., Assessment of the atrophogenicity potential of glucocorticoids by ultrasound and by epidermal biopsy under occlusive and nonocclusive conditions, Topical corticosteroid therapy, pp. 111-118, (1988)